Results 1 to 10 of about 313,710 (255)

In vitro and in silico modelling of ROS1-positive non-small cell lung cancer reveals fusion-dependent tyrosine kinase inhibitor responses. [PDF]

Mol Oncol
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Ul Haq F, Terrones M, Rodrigues Fortes F, Schepers A, Denis A, Deben C, Op de Beeck K, Van Camp G, Vandeweyer G.   +8 more
europepmc   +2 more sources

Survival Improvement With Steroid Use for Pulmonary Veno-Occlusive Disease With the Aid of Pulmonary Vasodilators and Tyrosine-Kinase Inhibitor, a Retrospective Study. [PDF]

Clin Cardiol
Finger M, Takeuchi K, Kikuchi H, Goda A, Inami T, Tamura Y, Kataoka M, Satoh T.   +7 more
europepmc   +1 more source

Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma. [PDF]

In Vivo
Oki M, Ohba K, Mukae Y, Matsuda T, Nakanishi H, Mitsunari K, Matsuo T, Mochizuki Y, Imamura R.   +8 more
europepmc   +1 more source

Covalent Bruton's tyrosine kinase inhibitor HZ-A-018 in patients with relapsed or refractory B cell malignancies: A multicenter phase I study. [PDF]

iScience
Wu G, Wei J, Yang H, Fan L, Yu S, Zhang J, Lin M, Zhou H, Xu N, Hu M, Zhou X, Jin J, Qian W, Shentu J.   +13 more
europepmc   +1 more source

Liver metastasis from follicular thyroid carcinoma successfully treated with hepatectomy and tyrosine kinase inhibitor: a case report. [PDF]

J Surg Case Rep
Heng HE, Chow TK, Ng KL, Koh PS.
europepmc   +1 more source

Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2. [PDF]

Cancer Rep (Hoboken)
Espinoza-Gutarra MR, Jarret B, Wang X, Afghahi A, Bae S.   +4 more
europepmc   +1 more source

Decoding BCR::ABL1 kinase domain mutations in chronic myeloid leukemia: Implications for tyrosine kinase inhibitor resistance in a South Asian population. [PDF]

Hematol Transfus Cell Ther
Sharif F, Mahmood R, Roghani M, Khan SH, Khan I.   +4 more
europepmc   +1 more source

Chronic myeloid leukemia in resource-limited settings: Navigating treatment challenges amid limited tyrosine kinase inhibitor access. [PDF]

J Int Med Res
Aamir Z, Kaleem B, Hassan SJ, Hafeez A, Jabeen A, Zehra SA, Mansoor N.   +6 more
europepmc   +1 more source